Fortrea Holdings (FTRE) Operating Income (2022 - 2026)
Fortrea Holdings (FTRE) posted Operating Income of -$3.4 million for Q1 2026, up 75.0% on a QoQ basis from -$13.6 million in Q4 2025, and up 99.35% year-over-year from -$1.7 million in Q1 2025.
Fortrea Holdings (FTRE) Operating Income (2022 - 2026) Analysis & Trends
Fortrea Holdings' Operating Income history runs 5 years deep, the most recent figure standing at -$3.4 million for Q1 2026.
- Quarterly Operating Income rose 99.35% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$355.9 million (up 44.79% YoY) and the FY2025 annual result came in at -$872.6 million, down 438.97% from the prior year.
- Operating Income was -$3.4 million for Q1 2026 at Fortrea Holdings, up from -$13.6 million in the prior quarter.
- Across five years, Operating Income topped out at $71.2 million in Q2 2022 and bottomed at -$520.1 million in Q1 2025.
- A 5-year average of -$53.2 million and a median of -$11.1 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income tumbled 1290.64% — and 2026, when it soared 99.35%.
- Fortrea Holdings' Operating Income stood at $14.3 million in 2022, then slumped by 267.83% to -$24.0 million in 2023, then tumbled by 131.67% to -$55.6 million in 2024, then surged by 75.54% to -$13.6 million in 2025, then soared by 75.0% to -$3.4 million in 2026.
- Business Quant data shows FTRE's Operating Income at -$3.4 million in Q1 2026, -$13.6 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -13.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -330.30 Mn |
| Mar 31, 2025 | -520.10 Mn |
| Dec 31, 2024 | -55.60 Mn |
| Sep 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -50.90 Mn |
| Mar 31, 2024 | -37.40 Mn |
| Dec 31, 2023 | -24.00 Mn |
| Sep 30, 2023 | 10.30 Mn |
| Jun 30, 2023 | 31.60 Mn |
| Mar 31, 2023 | 14.10 Mn |
| Dec 31, 2022 | 14.30 Mn |
| Sep 30, 2022 | 68.90 Mn |
| Jun 30, 2022 | 71.20 Mn |